{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:37:48Z","timestamp":1788907068263,"version":"build-2803163510"},"reference-count":27,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["22\/574"],"award-info":[{"award-number":["22\/574"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,7,19]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Gout is one of the most common forms of arthritis worldwide. Gout is particularly prevalent in Aotearoa\/New Zealand and is estimated to affect 13.1% of M\u0101ori men, 22.9% of Pacific men and 7.4% of New Zealand European men. Effective long-term treatment requires lowering serum urate to &lt;0.36\u2009mmol\/L. Allopurinol is the most commonly used urate-lowering medication worldwide. Despite its efficacy and safety, the allopurinol dose escalation treat-to-target serum urate strategy is difficult to implement and there are important inequities in allopurinol prescribing in Aotearoa. The escalation strategy is labour intensive, time consuming and costly for people with gout and the healthcare system. An easy and effective way to dose-escalate allopurinol is required, especially as gout disproportionately affects working-age M\u0101ori men and Pacific men, who frequently do not receive optimal care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>: A 12-month non-inferiority randomised controlled trial in people with gout who have a serum urate \u2265 0.36 mmol\/l will be undertaken. 380 participants recruited from primary and secondary care will be randomised to one of the two allopurinol dosing strategies: intensive nurse-led treat-to-target serum urate dosing (intensive treat-to-target) or protocol-driven dose escalation based on dose predicted by an allopurinol dosing model (Easy-Allo). The primary endpoint will be the proportion of participants who achieve target serum urate (&lt;0.36\u2009mmol\/L) at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The New Zealand Northern B Health and Disability Ethics Committee approved the study (2022 FULL 13478). Results will be disseminated in peer-reviewed journals and to participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN12622001279718p.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-084665","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T13:02:44Z","timestamp":1722690164000},"page":"e084665","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Easing the way to achieving target serum urate in people with gout: protocol for a non-inferiority randomised strategy trial using an allopurinol dosing model in Aotearoa\/New Zealand (the Easy-Allo Study)"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-2912","authenticated-orcid":false,"given":"Lisa","family":"Stamp","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Te Karu","sequence":"additional","affiliation":[{"name":"Department of General Practice and Primary Health Care, University of Auckland, Auckland, Aotearoa New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Reid","sequence":"additional","affiliation":[{"name":"Health Literacy NZ, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F B","family":"Wright","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Frampton","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vui Suli","family":"Tuitaupe","sequence":"additional","affiliation":[{"name":"Nil, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-4476","authenticated-orcid":false,"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[{"name":"Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"2025120519224888000_14.8.e084665.1","unstructured":"Atlas of Healthcare Variation . Health qaulity and safety commission of new zealand; gout domain 2021. n.d. Available: www.hqsc.govt.nz\/atlas"},{"key":"2025120519224888000_14.8.e084665.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"2025120519224888000_14.8.e084665.3","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American college of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care & Research"},{"key":"2025120519224888000_14.8.e084665.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.04.011"},{"key":"2025120519224888000_14.8.e084665.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32158-5"},{"key":"2025120519224888000_14.8.e084665.6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.31128\/AJGP-04-19-4909","article-title":"The challenges of managing gout in primary care: results of a best-practice audit","volume":"48","author":"Stamp","year":"2019","journal-title":"Aust J Gen Pract"},{"key":"2025120519224888000_14.8.e084665.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.34488"},{"key":"2025120519224888000_14.8.e084665.8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: The LASSO study","volume":"45","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2025120519224888000_14.8.e084665.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209213"},{"key":"2025120519224888000_14.8.e084665.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210872"},{"key":"2025120519224888000_14.8.e084665.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211873"},{"key":"2025120519224888000_14.8.e084665.12","unstructured":"Te Karu L , Arroll B , Bryant L , et al . The inequity of access to health: A case study of patients with gout in one general practice. NZ Med J 2021."},{"key":"2025120519224888000_14.8.e084665.13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/bcp.13516","article-title":"The impact of diuretic use andABCG2genotype on the predictive performance of a published allopurinol dosing tool","volume":"84","author":"Wright","year":"2018","journal-title":"Brit J Clinical Pharma"},{"key":"2025120519224888000_14.8.e084665.14","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12799"},{"key":"2025120519224888000_14.8.e084665.15","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/bcp.16005","article-title":"The development and evaluation of dose\u2010prediction tools for allopurinol therapy (Easy\u2010Allo tools)","volume":"90","author":"Wright","year":"2024","journal-title":"Brit J Clinical Pharma"},{"key":"2025120519224888000_14.8.e084665.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208237"},{"key":"2025120519224888000_14.8.e084665.17","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care & Research"},{"key":"2025120519224888000_14.8.e084665.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"2025120519224888000_14.8.e084665.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1169"},{"key":"2025120519224888000_14.8.e084665.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"key":"2025120519224888000_14.8.e084665.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"2025120519224888000_14.8.e084665.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100990"},{"key":"2025120519224888000_14.8.e084665.23","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211028007","article-title":"Inequities in people with gout: a focus on M\u0101ori (Indigenous People) of aotearoa New Zealand","volume":"13","author":"Te Karu","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025120519224888000_14.8.e084665.24","first-page":"8","article-title":"Gout in aotearoa New Zealand: the equity crisis continues in plain sight","volume":"131","author":"Dalbeth","year":"2018","journal-title":"N Z Med J"},{"key":"2025120519224888000_14.8.e084665.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-019-0815-8","article-title":"Consolidated criteria for strengthening reporting of health research involving indigenous peoples: the consider statement","volume":"19","author":"Huria","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"2025120519224888000_14.8.e084665.26","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22741","article-title":"Development of preliminary remission criteria for gout using delphi and 1000minds consensus exercises","volume":"68","author":"de Lautour","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025120519224888000_14.8.e084665.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090370"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-084665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:22:59Z","timestamp":1764991379000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-084665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,3]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/bmjopen-2024-084665"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-084665","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}